Scynexis Financials
Scynexis (SCYX) reported $20.6M in revenue for fiscal year 2025, up 449.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Lumpy revenue sits atop a development-heavy cost base, while 2025 liquidity improved mainly through non-operating cash movements.
2025’s operating recovery did not make the business self-funding: R&D spending exceeded revenue, while operating cash flow remained negative. Cash rose from$16.1M in 2024 to$21.3M in 2025 despite negative operating cash flow, so the liquidity improvement was not produced by core operations.
The 2023 revenue and profit spike was followed by a 2024 collapse and a 2025 rebound to
In 2025, R&D investment of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Scynexis's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Scynexis, and counted as zero in the overall score.
Scynexis scores -5.77, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($51.6M) relative to total liabilities ($9.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Scynexis passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Scynexis reported a net loss of $8.6M while operations used $5.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Scynexis reported an operating loss of $16.1M against $173K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Scynexis generated $20.6M in revenue in fiscal year 2025. This represents an increase of 449.9% from the prior year.
Scynexis reported -$8.6M in net income in fiscal year 2025. This represents an increase of 59.6% from the prior year.
Scynexis earned -$0.17 per diluted share (EPS) in fiscal year 2025. This represents an increase of 61.4% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Scynexis held $21.3M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Scynexis's operating margin was -78.0% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Scynexis's net profit margin was -41.8% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Scynexis's ROE was -17.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 21.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Scynexis invested $22.3M in research and development in fiscal year 2025. This represents a decrease of 15.6% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
SCYX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.2M | $20.6M+449.9% | $3.7M-97.3% | $140.1M+2652.7% | $5.1M-61.3% | $13.2M | $0-100.0% | $121K-52.9% | $257K0.0% | $257K0.0% | $257K0.0% | $257K-97.8% | $11.7M+22.6% | $9.6M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $15.4M-5.3% | $16.3M |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$3.7M+44.9% | -$6.7M |
| R&D Expenses | $26.2M | $22.3M-15.6% | $26.4M-14.6% | $30.9M+13.5% | $27.3M+14.7% | $23.8M-34.9% | $36.5M-4.9% | $38.4M+78.1% | $21.6M+17.6% | $18.3M-8.7% | $20.1M+22.1% | $16.4M+98.4% | $8.3M+89.9% | $4.4M |
| SG&A Expenses | $15.6M | $14.4M-0.4% | $14.5M-30.9% | $20.9M-66.8% | $63.0M+26.1% | $49.9M+241.3% | $14.6M+37.4% | $10.6M+22.7% | $8.7M+5.2% | $8.3M+3.2% | $8.0M-34.3% | $12.2M+59.7% | $7.6M+73.8% | $4.4M |
| Operating Income | -$22.6M | -$16.1M+56.7% | -$37.1M-151.1% | $72.7M+184.7% | -$85.8M-41.0% | -$60.8M-18.9% | -$51.1M-4.6% | -$48.9M-63.2% | -$30.0M-13.9% | -$26.3M+5.4% | -$27.8M+1.9% | -$28.3M-93.5% | -$14.6M-69.3% | -$8.6M |
| Interest Expense | $0 | $173K-79.1% | $828K-73.5% | $3.1M-39.8% | $5.2M+95.4% | $2.7M+125.2% | $1.2M+19.8% | $986K-39.4% | $1.6M+11.8% | $1.5M+314.5% | $351K+3290.9% | -$11K-122.9% | $48K | N/A |
| Income Tax | N/A | $0-100.0% | $151K+9.4% | $138K+102.9% | -$4.7M-52.2% | -$3.1M+1.9% | -$3.1M | $0+100.0% | -$6.7M | $0 | $0 | $0+100.0% | -$1.2M-102.8% | -$575K |
| Net Income | -$10.2M | -$8.6M+59.6% | -$21.3M-131.8% | $67.0M+206.7% | -$62.8M-91.1% | -$32.9M+40.4% | -$55.2M-2.7% | -$53.7M-330.8% | -$12.5M+50.2% | -$25.1M+16.4% | -$30.0M+8.1% | -$32.6M-670.5% | -$4.2M+86.1% | -$30.5M |
| EPS (Diluted) | — | -$0.17+61.4% | -$0.44-131.7% | $1.39+194.6% | -$1.47 | -$1.25 | N/A | N/A | N/A | N/A | -$1.58 | -$2.68 | -$2.69 | -$139.47 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SCYX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $59.0M-34.9% | $90.6M-29.4% | $128.4M+46.2% | $87.8M-26.7% | $119.8M+16.9% | $102.5M+79.4% | $57.2M+7.5% | $53.2M+16.0% | $45.9M-23.3% | $59.8M+21.3% | $49.3M+24.2% | $39.7M+220.3% | $12.4M |
| Current Assets | $40.4M-44.1% | $72.2M-29.3% | $102.1M+29.2% | $79.1M-27.7% | $109.4M+11.4% | $98.2M+87.4% | $52.4M+1.8% | $51.5M+14.5% | $45.0M-24.2% | $59.3M+22.5% | $48.4M+22.2% | $39.6M+369.6% | $8.4M |
| Cash & Equivalents | $21.3M+32.4% | $16.1M-52.9% | $34.0M-25.7% | $45.8M-56.2% | $104.5M+12.3% | $93.0M+121.9% | $41.9M+266.5% | $11.4M-0.3% | $11.5M-67.8% | $35.7M-24.1% | $47.0M+45.7% | $32.2M+2199.8% | $1.4M |
| Inventory | N/A | N/A | $0-100.0% | $899K+94.2% | $463K | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | $0-100.0% | $2.1M+144.0% | $861K | $0 | N/A | N/A | N/A | N/A | N/A | $1.1M+55.5% | $719K |
| Total Liabilities | $9.7M-72.9% | $35.6M-35.9% | $55.5M-34.4% | $84.6M+7.6% | $78.6M-1.5% | $79.8M+80.3% | $44.3M+101.7% | $21.9M-10.2% | $24.4M-2.1% | $25.0M+241.0% | $7.3M+17.4% | $6.2M-94.8% | $120.5M |
| Current Liabilities | $5.7M-76.2% | $24.1M+47.8% | $16.3M-7.5% | $17.6M+29.4% | $13.6M-48.4% | $26.4M+139.7% | $11.0M+87.4% | $5.9M-42.1% | $10.1M+172.9% | $3.7M-44.2% | $6.7M+24.6% | $5.3M-73.2% | $20.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | $34.4M | N/A | $0-100.0% | $15.1M+46.4% | $10.3M-27.7% | $14.3M | $0 | N/A | N/A |
| Total Equity | $49.4M-10.4% | $55.1M-24.5% | $73.0M+2156.8% | $3.2M-92.2% | $41.3M+81.3% | $22.8M+76.5% | $12.9M-58.7% | $31.2M+45.8% | $21.4M-38.5% | $34.8M-17.0% | $41.9M+25.5% | $33.4M+130.9% | -$108.1M |
| Retained Earnings | -$385.1M-2.3% | -$376.5M-6.0% | -$355.2M+15.9% | -$422.3M-17.5% | -$359.5M-10.1% | -$326.6M-20.3% | -$271.4M-24.7% | -$217.7M-6.1% | -$205.3M-13.9% | -$180.1M-20.0% | -$150.1M-27.8% | -$117.5M-3.7% | -$113.3M |
Not reported in any period shown, so not listed: Goodwill.
SCYX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$13.3M | -$5.3M+78.0% | -$24.0M-139.9% | $60.2M+175.3% | -$79.9M-46.4% | -$54.6M-10.5% | -$49.4M-29.5% | -$38.1M-34.6% | -$28.3M-15.3% | -$24.6M+16.3% | -$29.4M-19.6% | -$24.5M-159.1% | -$9.5M-119.9% | -$4.3M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $4K | $0-100.0% | $565K+28150.0% | $2K-92.6% | $27K-95.4% | $589K-16.3% | $704K+63.3% | $431K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$54.6M-10.5% | -$49.4M-29.5% | -$38.1M-32.0% | -$28.9M-17.6% | -$24.6M+16.4% | -$29.4M-16.9% | -$25.1M-147.0% | -$10.2M-114.8% | -$4.7M |
| Investing Cash Flow | -$24.7M | $24.3M+295.2% | $6.2M+117.6% | -$34.9M-27.3% | -$27.4M-2236.9% | -$1.2M-118.1% | $6.5M-75.3% | $26.2M+3367.7% | -$803K+91.7% | -$9.6M+57.2% | -$22.5M-1516.9% | $1.6M+425.0% | -$488K | N/A |
| Financing Cash Flow | $37.4M | -$14.2M-10094.2% | -$139K+99.6% | -$36.7M-175.6% | $48.6M-27.6% | $67.1M-28.6% | $94.0M+122.2% | $42.3M+43.8% | $29.4M+194.6% | $10.0M-75.3% | $40.5M+7.4% | $37.7M-7.6% | $40.8M | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SCYX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -31.6%+38.8pp | -70.4% |
| Operating Margin | -78.0% | -990.8% | 51.8% | -1684.5% | -462.2% | N/A | -40430.6% | -11666.5% | -10241.3% | -10823.7% | -11030.7% | -124.8% | -90.4% |
| Net Margin | -41.8% | -568.3% | 47.8% | -1233.7% | -249.7% | N/A | -44388.4% | -4851.4% | -9751.0% | -11668.9% | -12693.8% | -36.1% | -318.3% |
| Return on Equity | -17.4%+21.2pp | -38.6%-130.5pp | 91.9%+2034.6pp | -1942.7%-1863.1pp | -79.7%+162.8pp | -242.5%+174.0pp | -416.5%-376.6pp | -39.9%+77.1pp | -117.1%-30.9pp | -86.1%-8.4pp | -77.8%-65.1pp | -12.7% | N/A |
| Return on Assets | -14.6%+8.9pp | -23.5%-75.7pp | 52.2%+123.7pp | -71.5%-44.1pp | -27.4%+26.4pp | -53.8%+40.2pp | -94.0%-70.5pp | -23.4%+31.2pp | -54.7%-4.5pp | -50.2%+16.0pp | -66.2%-55.5pp | -10.7%+235.2pp | -245.9% |
| Current Ratio | 7.04+4.0x | 3.00-3.3x | 6.26+1.8x | 4.49-3.5x | 8.03+4.3x | 3.72-1.0x | 4.76-4.0x | 8.76+4.3x | 4.43-11.5x | 15.96+8.7x | 7.27-0.1x | 7.41+7.0x | 0.42 |
| Debt-to-Equity | 0.20-0.5x | 0.65-0.1x | 0.76-25.4x | 26.16+25.3x | 0.83-2.7x | 3.51+3.5x | 0.00-0.5x | 0.480.0x | 0.48+0.1x | 0.41+0.4x | 0.00-0.2x | 0.19 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | -414.5% | N/A | -31503.3% | -11240.5% | -9555.6% | -11431.9% | -9779.8% | -86.7%-37.2pp | -49.5% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Scynexis Ranks
Frequently Asked Questions
What is Scynexis's annual revenue?
Scynexis (SCYX) reported $20.6M in total revenue for fiscal year 2025. This represents a 449.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Scynexis's revenue growing?
Scynexis (SCYX) revenue grew by 449.9% year-over-year, from $3.7M to $20.6M in fiscal year 2025.
Is Scynexis profitable?
No, Scynexis (SCYX) reported a net income of -$8.6M in fiscal year 2025, with a net profit margin of -41.8%.
What is Scynexis's operating margin?
Scynexis (SCYX) had an operating margin of -78.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Scynexis's net profit margin?
Scynexis (SCYX) had a net profit margin of -41.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Scynexis's return on equity (ROE)?
Scynexis (SCYX) has a return on equity of -17.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Scynexis's operating cash flow?
Scynexis (SCYX) recorded an outflow of $5.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Scynexis's total assets?
Scynexis (SCYX) had $59.0M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Scynexis spend on research and development?
Scynexis (SCYX) invested $22.3M in research and development during fiscal year 2025.
What is Scynexis's current ratio?
Scynexis (SCYX) had a current ratio of 7.04 as of fiscal year 2025, which is generally considered healthy.
What is Scynexis's debt-to-equity ratio?
Scynexis (SCYX) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Scynexis's return on assets (ROA)?
Scynexis (SCYX) had a return on assets of -14.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Scynexis's Altman Z-Score?
Scynexis (SCYX) has an Altman Z-Score of -5.77, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Scynexis's Piotroski F-Score?
Scynexis (SCYX) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Scynexis's earnings high quality?
Scynexis (SCYX) reported a net loss of $8.6M while operations used $5.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Scynexis cover its interest payments?
Scynexis (SCYX) reported an operating loss of $16.1M against $173K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Scynexis?
Scynexis (SCYX) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.